AWAK Technologies: Funding, Investors & Team (Sep 2026)

AWAK Technologies is a company that specializes in the development of wearable dialysis machines. These machines are lightweight, weighing only 1kg, and are powered by batteries, allowing for continuous dialysis. The company received certification in September 2008 for its ISO 13485 Quality Management System, which recognizes its ability to design, manufacture, and distribute medical devices. The technology behind their product, known as the Automated Wearable Artificial Kidney (AWAK), is based on tidal peritoneal dialysis and was researched by Profs David Lee & Martin Roberts of UCLA and VA Systems. The engineering and development of the AWAK machine is conducted in Singapore in collaboration with Temasek Polytechnic. Currently, the company has completed its research and development phase and is in the clinical trial stage, aiming to obtain both FDA and CE certifications. The AWAK Regular Cartridge, which is a component of the wearable artificial kidney, is currently in the pilot production stage and is expected to undergo clinical trials by the end of 2012. This innovative device operates continuously and mimics the function of a normal kidney. Its small size, light weight, and battery-operated design allow patients to maintain their daily routines without restriction, including work, travel, and leisure activities.

AWAK Technologies has raised $20.0M across 1 round on record. The most recent is a Series B of $20.0M announced in Sep 2023.

AWAK Technologies' most recent funding round on record is a Series B of $20.0M, announced in Sep 2023.

Neo Kok Beng is listed as CEO at AWAK Technologies.

AWAK Technologies is based in Burbank, California, United States.

AWAK Technologies is in the 51-100 employee band.

AWAK Technologies' latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.